Canada · Delayed Price · Currency is CAD Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of CAD 164.75 million. The enterprise value is 183.03 million.
| Market Cap | 164.75M |
| Enterprise Value | 183.03M |
Important Dates
The last earnings date was Monday, January 26, 2026.
| Earnings Date | Jan 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cannara Biotech has 95.78 million shares outstanding. The number of shares has increased by 2.18% in one year.
| Current Share Class | 95.78M |
| Shares Outstanding | 95.78M |
| Shares Change (YoY) | +2.18% |
| Shares Change (QoQ) | +3.00% |
| Owned by Insiders (%) | 5.81% |
| Owned by Institutions (%) | 0.23% |
| Float | 40.80M |
Valuation Ratios
The trailing PE ratio is 14.43 and the forward PE ratio is 10.12.
| PE Ratio | 14.43 |
| Forward PE | 10.12 |
| PS Ratio | 1.47 |
| PB Ratio | 1.48 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | 13.31 |
| P/OCF Ratio | 7.44 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.82, with an EV/FCF ratio of 14.78.
| EV / Earnings | 15.50 |
| EV / Sales | 1.63 |
| EV / EBITDA | 6.82 |
| EV / EBIT | 9.09 |
| EV / FCF | 14.78 |
Financial Position
The company has a current ratio of 2.70, with a Debt / Equity ratio of 0.31.
| Current Ratio | 2.70 |
| Quick Ratio | 1.01 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.30 |
| Debt / FCF | 2.81 |
| Interest Coverage | 6.06 |
Financial Efficiency
Return on equity (ROE) is 11.70% and return on invested capital (ROIC) is 10.74%.
| Return on Equity (ROE) | 11.70% |
| Return on Assets (ROA) | 7.51% |
| Return on Invested Capital (ROIC) | 10.74% |
| Return on Capital Employed (ROCE) | 14.14% |
| Weighted Average Cost of Capital (WACC) | 6.13% |
| Revenue Per Employee | 248,330 |
| Profits Per Employee | 26,128 |
| Employee Count | 452 |
| Asset Turnover | 0.67 |
| Inventory Turnover | 1.37 |
Taxes
In the past 12 months, Cannara Biotech has paid 5.29 million in taxes.
| Income Tax | 5.29M |
| Effective Tax Rate | 30.95% |
Stock Price Statistics
The stock price has increased by +57.80% in the last 52 weeks. The beta is 0.32, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +57.80% |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 1.64 |
| Relative Strength Index (RSI) | 40.93 |
| Average Volume (20 Days) | 60,095 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of CAD 112.25 million and earned 11.81 million in profits. Earnings per share was 0.12.
| Revenue | 112.25M |
| Gross Profit | 48.13M |
| Operating Income | 20.13M |
| Pretax Income | 17.10M |
| Net Income | 11.81M |
| EBITDA | 26.56M |
| EBIT | 20.13M |
| Earnings Per Share (EPS) | 0.12 |
Balance Sheet
The company has 16.52 million in cash and 34.80 million in debt, with a net cash position of -18.29 million or -0.19 per share.
| Cash & Cash Equivalents | 16.52M |
| Total Debt | 34.80M |
| Net Cash | -18.29M |
| Net Cash Per Share | -0.19 |
| Equity (Book Value) | 111.21M |
| Book Value Per Share | 1.17 |
| Working Capital | 53.54M |
Cash Flow
In the last 12 months, operating cash flow was 22.14 million and capital expenditures -9.76 million, giving a free cash flow of 12.38 million.
| Operating Cash Flow | 22.14M |
| Capital Expenditures | -9.76M |
| Free Cash Flow | 12.38M |
| FCF Per Share | 0.13 |
Margins
Gross margin is 42.88%, with operating and profit margins of 17.93% and 10.52%.
| Gross Margin | 42.88% |
| Operating Margin | 17.93% |
| Pretax Margin | 15.24% |
| Profit Margin | 10.52% |
| EBITDA Margin | 23.66% |
| EBIT Margin | 17.93% |
| FCF Margin | 11.03% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.18% |
| Shareholder Yield | -2.18% |
| Earnings Yield | 7.17% |
| FCF Yield | 7.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 2.65 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.65 |
| Piotroski F-Score | 8 |